🇺🇸 FDA
Patent

US 10738124

Anti-EGFRvIII antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10738124 (Anti-EGFRvIII antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558